Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Marini

Showing results (111-120 of 190) with videos related to

Pageof 19
Sort By:
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|June 2, 2021
Real world use of FLT3 inhibitors for treatment of FLT3+ acute myeloid leukemia (AML): A single center, propensity-score matched, retrospective cohort studyBrian G Bazzell, Bernard L Marini, Lydia L Benitez, et al.
Patient Education and Counseling|June 26, 2014
The effects of an informational video on patient knowledge, satisfaction and compliance with venous thromboembolism prophylaxis: a pilot studyBernard L Marini, Kylee Funk, Michael D Kraft, et al.
The Journal of Antimicrobial Chemotherapy|November 2, 2017
Risk factors for subtherapeutic levels of posaconazole tabletLaura A Tang, Bernard L Marini, Lydia Benitez, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 24, 2021
Evaluating the Role of Novel Oncology Agents: Oncology Stewardship in Relapsed/Refractory Diffuse Large B-Cell LymphomaBrian G Bazzell, Lydia L Benitez, Bernard L Marini, et al.
Leukemia & Lymphoma|November 20, 2019
Impact of prophylactic intrathecal chemotherapy on CNS relapse rates in AML patients presenting with hyperleukocytosisJustin H Reid, Anthony J Perissinotti, Lydia Benitez, et al.
Cancer|July 11, 2019
Mini-HCVD plus inotuzumab plus or minus blinatumomab: Hype or hope?Bernard L Marini, Anthony J Perissinotti, Dale L Bixby, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|August 17, 2021
Clinical Availability of ATRA for Patients With Suspected Acute Promyelocytic Leukemia: Why Guidelines May Not Be FollowedMarcus J Geer, Charles E Foucar, Sumana Devata, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|July 2, 2020
Role of caplacizumab in the treatment of acquired thrombotic thrombocytopenic purpuraJustin H Reid, Karin M Durant, Sheh-Li Chen, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 22, 2021
Propensity-score Matched Comparison of Salvage Chemotherapy Regimens in Relapsed/Refractory Acute Myeloid LeukemiaJustin H Reid, Bernard L Marini, Lydia L Benitez, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 13, 2019
Lenalidomide Plus Hypomethylating Agent as a Treatment Option in Acute Myeloid Leukemia With Recurrent Genetic Abnormalities-AML With inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOMLauren E Merz, Anthony J Perissinotti, Bernard L Marini, et al.
Pageof 19

Showing results (111-120 of 190) with videos related to

Sort By:
Pageof 19
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|June 2, 2021
Real world use of FLT3 inhibitors for treatment of FLT3+ acute myeloid leukemia (AML): A single center, propensity-score matched, retrospective cohort studyBrian G Bazzell, Bernard L Marini, Lydia L Benitez, et al.
Patient Education and Counseling|June 26, 2014
The effects of an informational video on patient knowledge, satisfaction and compliance with venous thromboembolism prophylaxis: a pilot studyBernard L Marini, Kylee Funk, Michael D Kraft, et al.
The Journal of Antimicrobial Chemotherapy|November 2, 2017
Risk factors for subtherapeutic levels of posaconazole tabletLaura A Tang, Bernard L Marini, Lydia Benitez, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 24, 2021
Evaluating the Role of Novel Oncology Agents: Oncology Stewardship in Relapsed/Refractory Diffuse Large B-Cell LymphomaBrian G Bazzell, Lydia L Benitez, Bernard L Marini, et al.
Leukemia & Lymphoma|November 20, 2019
Impact of prophylactic intrathecal chemotherapy on CNS relapse rates in AML patients presenting with hyperleukocytosisJustin H Reid, Anthony J Perissinotti, Lydia Benitez, et al.
Cancer|July 11, 2019
Mini-HCVD plus inotuzumab plus or minus blinatumomab: Hype or hope?Bernard L Marini, Anthony J Perissinotti, Dale L Bixby, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|August 17, 2021
Clinical Availability of ATRA for Patients With Suspected Acute Promyelocytic Leukemia: Why Guidelines May Not Be FollowedMarcus J Geer, Charles E Foucar, Sumana Devata, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|July 2, 2020
Role of caplacizumab in the treatment of acquired thrombotic thrombocytopenic purpuraJustin H Reid, Karin M Durant, Sheh-Li Chen, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 22, 2021
Propensity-score Matched Comparison of Salvage Chemotherapy Regimens in Relapsed/Refractory Acute Myeloid LeukemiaJustin H Reid, Bernard L Marini, Lydia L Benitez, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 13, 2019
Lenalidomide Plus Hypomethylating Agent as a Treatment Option in Acute Myeloid Leukemia With Recurrent Genetic Abnormalities-AML With inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOMLauren E Merz, Anthony J Perissinotti, Bernard L Marini, et al.
Pageof 19